This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Catalog
ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
A Blueprint for Training and Development in GP2
This blog written by Dr. Alastair Noyce and Dr. Sara Bandres-Ciga discusses GP2’s plan to train students and investigators and the new considerations as a result of the COVID-19 pandemic.
A letter to the patient community from Randy Schekman, ASAP Scientific Director
This blog written by Dr. Randy Schekman and Benjamin Stecher describes the motivation and beginnings of the ASAP initiative. It also includes a letter written to the PD comunity by Dr. Schekman.
A possible role for VPS13-family proteins in bulk lipid transfer, membrane expansion, and organelle biogenesis.
This review focuses on the structure and function of the VPS13 family of proteins and discusses the prevailing hypthoses in the field regarding its role in lipid transport.
Teams
Themes
ALS- and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy
TBK1 mutations are linked to neurodegenerative disorders. The authors explored how TBK1 functions in PINK1/Parkin-dependent mitophagy and how mutations lead to disease. They found that TBK1 recruitment and kinase activity contributed to the clearance of damaged mitochondria (mitophagy). Further, they showed that TBK1 presence alone could disrupt the mitochondrial network. View preprint.
Teams
Themes
APEX-ATG8 proteomics with and without lysosomal damage
Proteomics data associated with DOI: 10.7554/eLife.72328
Teams
Themes
APEX-autophagy cargo receptor proteomics with and without lysosomal damage
Proteomics data associated with DOI: 10.7554/eLife.72328
Teams
Themes
APEX-Galectin proteomics with and without lysosomal damage
Proteomics data associated with DOI: 10.7554/eLife.72328
Teams
Themes
Applying for GP2 Data Access on the AMP® PD Platform
This blog written by Justin C. Solle, Claire Wegel, and Dr. Eline Appelmans outlines how to access GP2 on the AMP PD platform.
Assessing enrichment of proteins in the mitochondrial fraction in HEK cells
This is a method for measuring protein enrichment on mitochondria in various conditions. In the resulting Western blot, one can assess the level of contamination of other organelles in the enrichment prep.
Teams
Themes
ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization
ATP13A2 loss-of-function mutations cause lysosomal deficiency and are linked to Parkinson’s disease and alpha-synuclein pathology. The authors found that loss of ATP13A2 disrupts lysosomal membrane integrity and causes alpha-synuclein multimerization. Further, they showed that increased levels of ATP13A2 had a protective effect on alpha-synuclein aggregation.
Teams
Themes
ATP13A2-mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress
Loss-of-function of ATP13A2, an endo-lysosomal transporter that pumps polyamines into the cytosol, is associated with PD. ATP13A2 dysfunction causes polyamine accumulation within the lysosome and lysosomal rupture. The authors found a conserved cellular protective pathway involving ATP13A2-mediated lysosomal spermine export to provide protection against mitochondrial toxins.
Teams
Themes
Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease
This article assessed an established biomarker panel, validated in Alzheimer’s Disease, in a PD cohort
Building Clinical and Genetic Data for GP2 in the Cohort Integration Working Group
This blog written by Dr. Huw Morris describes how the cohort integration working group within GP2 is working to harmonize clinical data.